{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:33:16Z","timestamp":1777005196500,"version":"3.51.4"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In addition to gastroenteropancreatic neuroendocrine neoplasms, a wide variety of tumors express somatostatin receptors. Somatostatin receptor imaging, heavily utilized in neuroendocrine oncology, may also have utility in the diagnosis of other neoplasms and raises the possibility of potential therapeutic options. We describe the case of a 60-year-old man who underwent <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT, demonstrating an avid invasive pituitary macroadenoma. This mass was persistent and refractory despite traditional treatment options. Because of the avidity, <jats:sup>177<\/jats:sup>Lu-DOTATATE therapy was offered, although not ultimately performed, demonstrating a potential treatment for challenging cases utilizing the principles of theranostics.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003589","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T04:03:23Z","timestamp":1617077003000},"page":"505-506","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["68Ga-DOTATATE PET\/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit"],"prefix":"10.1097","volume":"46","author":[{"given":"Noah","family":"Lybik","sequence":"first","affiliation":[{"name":"University of Michigan Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Wale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","year":"2015","journal-title":"Radiographics"},{"key":"bib3-20250621","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ecl.2010.12.003","article-title":"Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"40","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib6-20250621","first-page":"e3986","article-title":"Neuroendocrine tumor therapy with lutetium-177: a literature review","volume":"11","year":"2019","journal-title":"Cureus"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.semnuclmed.2015.12.003","article-title":"Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer","volume":"46","year":"2016","journal-title":"Semin Nucl Med"},{"key":"bib9-20250621","first-page":"129","article-title":"Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome","volume":"35","year":"2006","journal-title":"Front Horm Res"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e038250","DOI":"10.1136\/bmjopen-2020-038250","article-title":"The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET\u2013positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size","volume":"10","year":"2020","journal-title":"BMJ Open"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","article-title":"Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma","volume":"17","year":"2014","journal-title":"Pituitary"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation","volume":"17","year":"2014","journal-title":"Pituitary"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:02:33Z","timestamp":1750539753000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003589","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}